Renal Protective Effect of DPP-4 Inhibitors in Type 2 Diabetes Mellitus Patients: A Cohort Study

Figure 2

Changes in eGFR 4 years before and 4 years after DPP-4i treatment initiation. Changes in eGFR in all patients (a) and in patients with macroalbuminuria (b), microalbuminuria (c), and normoalbuminuria (d). Baseline values are the means with standard errors. DPP-4i: dipeptidyl-peptidase IV inhibitor; UACR: urine albumin/creatinine ratio; −4 Y: 4 years before DPP-4i treatment initiation; −2 Y: 2 years before DPP-4i treatment initiation; 2 Y: 2 years after DPP-4i treatment initiation; 4 Y: 4 years after DPP-4i treatment initiation. value < 0.01.

(a)

(b)

(c)

(d)